108 related articles for article (PubMed ID: 22548315)
1. Enhanced prostate cancer targeting by modified protease sensitive photosensitizer prodrugs.
Zuluaga MF; Gabriel D; Lange N
Mol Pharm; 2012 Jun; 9(6):1570-9. PubMed ID: 22548315
[TBL] [Abstract][Full Text] [Related]
2. Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
Gabriel D; Busso N; So A; van den Bergh H; Gurny R; Lange N
J Control Release; 2009 Sep; 138(3):225-34. PubMed ID: 19445983
[TBL] [Abstract][Full Text] [Related]
3. Polymeric photosensitizer prodrugs for photodynamic therapy.
Campo MA; Gabriel D; Kucera P; Gurny R; Lange N
Photochem Photobiol; 2007; 83(4):958-65. PubMed ID: 17645670
[TBL] [Abstract][Full Text] [Related]
4. Selective photodetection and photodynamic therapy for prostate cancer through targeting of proteolytic activity.
Zuluaga MF; Sekkat N; Gabriel D; van den Bergh H; Lange N
Mol Cancer Ther; 2013 Mar; 12(3):306-13. PubMed ID: 23270928
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-sensitive dual fluorescence imaging and therapeutic agent for detection and treatment of synovial inflammation in murine rheumatoid arthritis.
Gabriel D; Lange N; Chobaz-Peclat V; Zuluaga MF; Gurny R; van den Bergh H; Busso N
J Control Release; 2012 Oct; 163(2):178-86. PubMed ID: 22959919
[TBL] [Abstract][Full Text] [Related]
6. Double-PEGylated Cyclopeptidic Photosensitizer Prodrug Improves Drug Uptake from In Vitro to Hen's Egg Chorioallantoic Membrane Model.
Bouilloux J; Kiening M; Yapi S; Lange N
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684822
[TBL] [Abstract][Full Text] [Related]
7. Tailoring protease-sensitive photodynamic agents to specific disease-associated enzymes.
Gabriel D; Campo MA; Gurny R; Lange N
Bioconjug Chem; 2007; 18(4):1070-7. PubMed ID: 17477499
[TBL] [Abstract][Full Text] [Related]
8. On the cutting edge: protease-sensitive prodrugs for the delivery of photoactive compounds.
Gabriel D; Zuluaga MF; Lange N
Photochem Photobiol Sci; 2011 May; 10(5):689-703. PubMed ID: 21298150
[TBL] [Abstract][Full Text] [Related]
9. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
10. ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer.
Jiang J; Loganathan J; Eliaz I; Terry C; Sandusky GE; Sliva D
Int J Oncol; 2012 May; 40(5):1339-44. PubMed ID: 22293856
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
13. Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: part II - co-loading of pheophorbide A and black hole quencher.
Bouilloux J; Yushchenko O; Dereka B; Boso G; Babič A; Zbinden H; Vauthey E; Lange N
Photochem Photobiol Sci; 2018 Nov; 17(11):1739-1748. PubMed ID: 30215090
[TBL] [Abstract][Full Text] [Related]
14. Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: part I - self-quenched prodrugs.
Bouilloux J; Yushchenko O; Dereka B; Boso G; Zbinden H; Vauthey E; Babič A; Lange N
Photochem Photobiol Sci; 2018 Nov; 17(11):1728-1738. PubMed ID: 30215073
[TBL] [Abstract][Full Text] [Related]
15. Polymeric nanoparticles for photodynamic therapy.
Lee YE; Kopelman R
Methods Mol Biol; 2011; 726():151-78. PubMed ID: 21424449
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
Chung DE; Kratz F
Bioorg Med Chem Lett; 2006 Oct; 16(19):5157-63. PubMed ID: 16875815
[TBL] [Abstract][Full Text] [Related]
17. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
18. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
20. Effect and mechanism of a new photodynamic therapy with glycoconjugated fullerene.
Otake E; Sakuma S; Torii K; Maeda A; Ohi H; Yano S; Morita A
Photochem Photobiol; 2010; 86(6):1356-63. PubMed ID: 20796243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
